GEN Exclusives

More »

The Lists

More »
Jun 10, 2013

10 Biotechnologies Yet to Live Up to the Hype

These technologies showed much promise at the start, but have yet to deliver.

10 Biotechnologies Yet to Live Up to the Hype

For various reasons, these products and technologies haven't come to fruition. [© fotoscool -]

  • There’s no argument that biotechnology has dramatically improved global healthcare with the introduction of many novel biotherapeutics. A few examples include Enbrel for the treatment of rheumatoid arthritis; Rituxan for non-Hodgkin’s lymphoma; Herceptin for breast cancer; Humulin for diabetes; Procrit for the treatment of anemia in patients with kidney failure, HIV, or cancer; and Avastin for metastatic colorectal cancer, advanced nonsquamous non–small cell lung cancer, metastatic kidney cancer, and glioblastoma.

    But along the way there have been some huge hopes for a number of other novel drug products and innovative technologies. For various reasons—they did not work as well as first thought or the market did not develop to the degree as had been expected—neither these products nor technologies have come to fruition. Here is GEN’s listing of ten biotechnologies that have yet to live up to the hype.

    • Antisense
    • Anti-sepsis drugs
    • Artificial blood substitutes
    • Bioremediation
    • HIV Vaccines
    • Interleukin 2
    • Novel antibiotic agents
    • Neurodegenerative and psychiatric disorder therapeutics
    • Transgenic-animal-produced therapies
    • Xenotransplantation

    Do you think innovations in biotechnology tend to be overhyped?

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »